| Objectives By collecting the clinicopathological data of patients with breast cancer(BC)diagnosed by postoperative pathology,and comparing the correlation between androgen receptor(AR)and molecular subtype,related parameters,and clinical characteristics based on different immunohistochemical scoring criterion in breast cancer.It is necessary to provide basis and reference for the clinical significance and application value of androgen receptor.Methods 1 Patients with breast cancer who treated in Hebei General Hospital from November 2019 to June 2021 were collected,included 268 cases.The expression of AR was evaluated according to the ASCO/CAP and H-score.The relationship between AR and clinical parameters(age,body mass index,menstruation status)and pathological parameters(ER,PR,HER2/erb B-2,histological grade,lymph node metastasis,pathological stage,Ki-67,p53 and molecular subtype)was analyzed.2 SPSS 25.0software was used for statistical analysis.Spearman test was used to compare the correlation between AR and clinicopathological parameters under different scoring criterion.The chi-square test was used to analyze the relationship between AR and clinicopathological parameters.The differences between groups were analyzed by Kruskal-Wallis statistical method.All statistical analyses were two-tailed and had a significance level(α)of 5%.Results 1 Correlation between AR and clinicopathological parameters under different scoring criterion.Under the ASCO/CAP criterion,the expression of AR(≥1%)was negatively correlated with Ki-67(P=0.033).Under the H-score criterion,the expression of AR(+~+++)was positively correlated with ER and PR,and negatively correlated with Ki-67,pathological stage,and tumor size(P<0.05).2 Correlation between AR and clinical parameters under different molecular subtype.In TNBC,the expression of AR(≥10%)was negatively correlated with Ki-67(P=0.039).In Luminal breast cancer,the expression of AR was positively correlated with ER and PR with different scoring criterion.Under the H-score criterion AR was negatively correlated with pathological stage(P=0.042).3 Under H-score criterion,different intensities of AR were positively correlated with age,ER and PR(P<0.05).With Ki-67,p53 and histological grade were negatively correlated(P<0.05).4 The relationship between Ki-67 and clinicopathological parameters.Under the H-score criterion Ki-67 was negatively correlated with AR(P=0.003).Ki-67 was negatively correlated with age,ER or PR(P<0.05),and positively correlated with HER2,p53,tumor size and lymph node metastasis(P<0.05).There was positive correlation between Ki-67 and histological grade,pathological stage(P<0.05).When Ki-67 was highly expressed((29)30%),the distribution of AR expression intensity in molecular subtype,ER,PR,p53 and histological grade were difference.5 The relationship between p53 and clinicopathological parameters.There was a negative correlation between p53 and AR,ER,PR(P<0.001),and a positive correlation between p53 and Ki-67,histological grade(P<0.001).6 Further study showed that under p53 negative(no mutation),low expression of Ki-67 was found in patients with strong positive of AR(+++),while high expression of Ki-67 followed AR negative(-)or mild(+)(P=0.011).In patients with AR negative expression,the intensity of p53 increased with the increase of Ki-67(P=0.034).7 Taking molecular subtype,in Luminal B,AR was positive with low expression of Ki-67(P=0.017).In addition,in luminal breast cancer and TNBC,there was significant difference between the intensity of p53 and Ki-67(P<0.05).Conclusions 1 Compared with HER2-enriched BC and TNBC,AR expression in luminal breast cancer was higher.2 AR(cut-off value ≥ 1% or H-score criterion)was negatively correlated with Ki-67,indicating that AR is one of the factors with better prognosis of BC.3 According to H-score criterion,the stronger intensity of AR,with the lower intensity of p53 and histological grade,and the earlier pathological stage,indicating that the intensity of AR expression also plays an important role in the prognosis of BC.Figure 5;Table 18;Reference 156... |